Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 5Plasma cell 2Classical hematology 1

Conditions

Multiple Myeloma 3082Neoplasms, Plasma Cell 614Lymphoma 455Lymphoma, Non-Hodgkin 428Recurrence 371Hodgkin Disease 366Leukemia, Lymphocytic, Chronic, B-Cell 362Precursor Cell Lymphoblastic Leukemia-Lymphoma 340Leukemia, Myeloid, Acute 322Leukemia 321Myelodysplastic Syndromes 287Lymphoma, Mantle-Cell 262Lymphoma, Large B-Cell, Diffuse 259Lymphoma, Follicular 254Lymphoma, B-Cell, Marginal Zone 231Burkitt Lymphoma 227Lymphoma, Large-Cell, Immunoblastic 203Myeloproliferative Disorders 197Immunoglobulin Light-chain Amyloidosis 184Neoplasms 182Hematologic Neoplasms 169Primary Myelofibrosis 167Leukemia, Myeloid, Chronic-Phase 165Leukemia, Myeloid, Accelerated Phase 154Lymphoma, T-Cell, Cutaneous 150Waldenstrom Macroglobulinemia 145Blast Crisis 143Leukemia, Myelomonocytic, Chronic 140Mycosis Fungoides 129Sezary Syndrome 128

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 1Immunoglobulins 1Hizentra 1Clavulanic Acid 1Ciprofloxacin 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Agammaglobulinemia × Plasma cell × Clear all
NCT06976476 2026-03-11

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
100 enrolled
Plasma cell

Agammaglobulinemia, Multiple Myeloma, Common Variable Immunodeficiency

NCT05678621 2024-04-19

RATIONALISE

Monash University

Phase 2/3 Recruiting
300 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Agammaglobulinemia, Infections, Leukemia, Lymphoma, Neoplasms, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡